10 results on '"Rossing, M."'
Search Results
2. A novel homozygous GFI1B variant in 2 sisters with thrombocytopenia and severe bleeding tendency.
- Author
-
Brøns N, Zaninetti C, Ostrowski SR, Petersen J, Greinacher A, Rossing M, and Leinøe E
- Subjects
- Adult, Female, Homozygote, Humans, Middle Aged, Mutation, Hemorrhage physiopathology, Proto-Oncogene Proteins metabolism, Repressor Proteins metabolism, Thrombocytopenia physiopathology
- Abstract
Genetic variants in growth factor-independent 1B ( GFI1B ), encoding transcription factor GFI1B, are causative of platelet-type bleeding disorder-17. Presently, 53 cases of GFI1B associated inherited thrombocytopenia (IT) have been published, however only three were homozygous. The bleeding- and platelet phenotypes of these patients depend on location and inheritance pattern of the GFI1B variant. We report a novel homozygous GFI1B (Thr174Ile) variant located in the first Zinc finger domain of GFI1B in two sisters of Palestinian ancestry born to consanguineous parents. They experienced severe bleeding tendency at moderately reduced platelet counts. Flow cytometry and immunofluorescent microscopy confirmed the diagnostic features of GFI1B associated IT: a reduced content of alpha granules and aberrant expression of the stem cell marker CD34 on platelets. Transcription factor GFI1B is differentially expressed during hemato- and lymphopoiesis. In addition, to platelet function investigations, we present results of lymphoid subgroup analyses and deformability of red cells measured by ektacytometry.
- Published
- 2021
- Full Text
- View/download PDF
3. Highly impaired platelet ultrastructure in two families with novel IKZF5 variants.
- Author
-
Leinoe E, Kjaersgaard M, Zetterberg E, Ostrowski S, Greinacher A, and Rossing M
- Subjects
- Child, Preschool, Female, Gene Expression Regulation, Humans, Middle Aged, Blood Platelets ultrastructure, Genetic Variation genetics, Ikaros Transcription Factor metabolism
- Abstract
Heterozygous variants in the IKZF5 gene, encoding transcription factor Pegasus, were recently discovered to be causal of inherited thrombocytopenia (IT). We screened 90 patients suspected of inherited thrombocytopenia for variants in 101 genes associated with inherited bleeding disorders and report the clinical presentation of two Danish families with novel variants in IKZF5. Platelet ultrastructure and cytoskeleton were evaluated by immunofluorescent microscopy (IF) and found to be highly abnormal, demonstrating severe disturbances of distribution and expression of non-muscular myosin, filamin, β-tubulin and α tubulin. Number of alpha granules were reduced, and platelets elongated when evaluated by TEM. In both families a child carrying a rare IKZF5 variant was affected by developmental delay. The proband of family A presented with recurrent infections and was examined for an immunodeficiency. The concentration of naive B-cells was found moderately reduced by leucocyte subpopulation examination, indicating an impaired cellular immunity. T-cells were marginally low with reduced share and concentration of CD45RApos, CD31pos, CD4pos recent thymic immigrants as signs of reduced thymic output. The novel IKZF5 variants co-segregated with thrombocytopenia in both families and both probands had significant bleeding tendency. Through comprehensive characterizations of the platelet morphology and function linked to the specific phenotypes we add novel insight to IKZF5 -associated thrombocytopenia, which may help to identify and classify more cases with IKZF5 associated IT.
- Published
- 2021
- Full Text
- View/download PDF
4. Molecular subtyping of breast cancer improves identification of both high and low risk patients.
- Author
-
Rossing M, Østrup O, Majewski WW, Kinalis S, Jensen MB, Knoop A, Kroman N, Talman ML, Hansen TVO, Ejlertsen B, and Nielsen FC
- Subjects
- BRCA2 Protein genetics, Breast Neoplasms pathology, Breast Neoplasms therapy, Carcinoma in Situ genetics, Carcinoma in Situ pathology, Carcinoma in Situ therapy, Carcinoma, Ductal, Breast genetics, Carcinoma, Ductal, Breast pathology, Carcinoma, Ductal, Breast therapy, Female, Germ-Line Mutation, Humans, Immunohistochemistry, Ki-67 Antigen genetics, Ki-67 Antigen metabolism, Middle Aged, RNA, Messenger metabolism, Receptor, ErbB-2 genetics, Receptor, ErbB-2 metabolism, Receptors, Estrogen genetics, Receptors, Estrogen metabolism, Receptors, Progesterone genetics, Receptors, Progesterone metabolism, Tissue Array Analysis, Ubiquitin-Protein Ligases genetics, Breast Neoplasms genetics, Clinical Decision-Making, Risk Assessment methods, Transcriptome
- Abstract
Background: Transcriptome analysis enables classification of breast tumors into molecular subtypes that correlate with prognosis and effect of therapy. We evaluated the clinical benefits of molecular subtyping compared to our current diagnostic practice., Materials and Methods: Molecular subtyping was performed on a consecutive and unselected series of 524 tumors from women with primary breast cancer (n = 508). Tumors were classified by the 256 gene expression signature (CIT) and compared to conventional immunohistochemistry (IHC) procedures., Results: More than 99% of tumors were eligible for molecular classification and final reports were available prior to the multidisciplinary conference. Using a prognostic standard mortality rate index (PSMRi) developed by the Danish Breast Cancer Group (DBCG) 39 patients were assigned with an intermediate risk and among these 16 (41%) were furthermore diagnosed by the multi-gene signature assigned with a luminal A tumor and consequently spared adjuvant chemotherapy. There was overall agreement between mRNA derived and IHC hormone receptor status, whereas IHC Ki67 protein proliferative index proved inaccurate, compared to the mRNA derived index. Forty-one patients with basal-like (basL) subtypes were screened for predisposing mutations regardless of clinical predisposition. Of those 17% carried pathogenic mutations., Conclusion: Transcriptome based subtyping of breast tumors evidently reduces the need for adjuvant chemotherapy and improves identification of women with predisposing mutations. The results imply that transcriptome profiling should become an integrated part of current breast cancer management.
- Published
- 2018
- Full Text
- View/download PDF
5. Characterization of basal-like subtype in a Danish consecutive primary breast cancer cohort.
- Author
-
Kinalis S, Nielsen FC, Talman ML, Ejlertsen B, and Rossing M
- Subjects
- Age Factors, BRCA1 Protein genetics, BRCA2 Protein genetics, Breast Neoplasms metabolism, Cohort Studies, Denmark, Female, Hedgehog Proteins metabolism, Heterozygote, Humans, Middle Aged, Mutation, Proto-Oncogene Proteins p21(ras) metabolism, Transcriptome, Triple Negative Breast Neoplasms metabolism, Up-Regulation, Wnt Signaling Pathway, Breast Neoplasms genetics, Breast Neoplasms pathology, Triple Negative Breast Neoplasms genetics, Triple Negative Breast Neoplasms pathology
- Abstract
Background: Transcriptome analysis enables classification of breast tumors into molecular subtypes. BRCA1/2 predisposed patients are more likely to suffer from a basal-like subtype and this group of patients displays a more distinct phenotype and genotype. Hence, in-depth characterization of this separate entity is needed., Material and Methods: Molecular subtyping was performed on a consecutive and unselected series of 1560 tumors from patients with primary breast cancer. Tumors were classified by the 256 gene expression signature (CIT) and associated with basic clinical characteristics and aggregated expression levels in the hallmark gene sets., Results: Of the 1560 samples, 168 were classified basal-like and 120 patients were screened for BRCA1/2 mutations, resulting in 19 BRCA1/2 carriers, 95 non-carriers and six patients carried variants of unknown significance. The BRCA1/2 carriers were significantly younger and there were no carriers above 60 years of age. The tumors showed a loss in DNA-repair profile, as well as an upregulation in proliferative cancer signaling pathways. A robust molecular signature for identification of the BRCA1/2 - carriers was infeasible in the current cohort. Patients with a basal like breast cancer had the lowest median age and the largest median tumor size. They were almost exclusively diagnosed in disease stage III., Conclusions: Basal-like subtype is indeed a separate entity compared with other molecular breast cancer subtypes and the clinical course for this patient group should reflect the aggressiveness of this cancer. Taken together, patients being diagnosed with a basal-like breast cancer are in the youngest segment of breast cancer patients and are mainly diagnosed in stage III disease.
- Published
- 2018
- Full Text
- View/download PDF
6. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.
- Author
-
Soenderstrup IMH, Laenkholm AV, Jensen MB, Eriksen JO, Gerdes AM, Hansen TVO, Kruse TA, Larsen MJ, Pedersen IS, Rossing M, Thomassen M, and Ejlertsen B
- Subjects
- Adolescent, Adult, Aged, Breast Neoplasms pathology, Breast Neoplasms therapy, Chemotherapy, Adjuvant, Denmark epidemiology, Disease-Free Survival, Female, Genetic Predisposition to Disease, Heterozygote, Humans, Mastectomy, Middle Aged, Neoplasm Recurrence, Local genetics, Neoplasm Recurrence, Local pathology, Registries, Young Adult, BRCA1 Protein genetics, BRCA2 Protein genetics, Breast Neoplasms genetics, Breast Neoplasms mortality, Mutation
- Abstract
Background: In breast cancer (BC) patients a cancer predisposing BRCA1/2 mutation is associated with adverse tumor characteristics, risk assessment and treatment allocation. We aimed to estimate overall- (OS) and disease-free survival (DFS) according to tumor characteristics and treatment among women who within two years of definitive surgery for primary BC were shown to carry a mutation in BRCA1/2 ., Material and Methods: From the clinical database of the Danish Breast Cancer Group we included 141 BRCA1 and 96 BRCA2 BC patients. Estrogen receptor and HER2 status were centrally reviewed on paraffin-embedded tumor tissue. Information on risk reducing surgery was obtained from the Danish Pathology and Patient Registries and included as time-dependent variables in Cox proportional hazard models., Results: Ten-year OS and DFS for BRCA1 BC patients were 78% (95% CI 69-85) and 74% (95% CI 64-81). Ten-year OS and DFS for BRCA2 BC were 88% (95% CI 78-94) and 84% (95% CI 74-91). BRCA1 BC patients as compared to BRCA2 BC patients had a higher risk of BC relapse or non-breast cancer within ten years of follow-up, independent of ER status (adjusted HR 2.78 95% CI 1.28-6.05, p = .01), but BRCA mutation was not associated with OS (adjusted HR 1.98, 95% CI 0.87-4.52, p = .10). In multivariate analysis, including both BRCA1 and BRCA2 carriers, no chemotherapy was associated with a higher risk of death (adjusted OS HR 3.58, 95% CI 1.29-9.97, p = .01) and risk reducing contralateral mastectomy (RRCM) was associated with a significantly reduced risk of death (adjusted OS HR 0.42, 95% CI =0.21-0.84, p = .01)., Conclusion: Difference in OS between BRCA1 and BRCA2 BC patients could be ascribed to tumor-biology. BRCA1 BC patients may have a shorter ten-year DFS than BRCA2 BC patients. Chemotherapy and risk reducing contralateral mastectomy reduce mortality for both BRCA1 and BRCA2 BC patients.
- Published
- 2018
- Full Text
- View/download PDF
7. A Danish national effort of BRCA1/2 variant classification.
- Author
-
Pedersen IS, Schmidt AY, Bertelsen B, Ernst A, Andersen CLT, Kruse T, Rossing M, and Thomassen M
- Subjects
- Alleles, Denmark, Female, Humans, Mutation, Breast Neoplasms classification, Breast Neoplasms genetics, Genes, BRCA1, Genes, BRCA2
- Published
- 2018
- Full Text
- View/download PDF
8. Germline heterozygous variants in genes associated with familial hemophagocytic lymphohistiocytosis as a cause of increased bleeding.
- Author
-
Fager Ferrari M, Leinoe E, Rossing M, Norström E, Strandberg K, Steen Sejersen T, Qvortrup K, and Zetterberg E
- Subjects
- Adolescent, Adult, Blood Platelets metabolism, Blood Platelets ultrastructure, Child, Child, Preschool, Comorbidity, Female, Flow Cytometry, Humans, Lymphohistiocytosis, Hemophagocytic diagnosis, Lymphohistiocytosis, Hemophagocytic metabolism, Male, Membrane Proteins genetics, Middle Aged, Models, Biological, Munc18 Proteins genetics, Platelet Count, Qa-SNARE Proteins genetics, Secretory Vesicles metabolism, Secretory Vesicles ultrastructure, Whole Genome Sequencing, Young Adult, Genetic Predisposition to Disease, Germ-Line Mutation, Hemorrhage etiology, Heterozygote, Lymphohistiocytosis, Hemophagocytic complications, Lymphohistiocytosis, Hemophagocytic genetics, Mutation
- Abstract
Familial hemophagocytic lymphohistiocytosis (FHL) is caused by biallelic variants in genes regulating granule secretion in cytotoxic lymphocytes. In FHL3-5, the affected genes UNC13D, STX11 and STXBP2 have further been shown to regulate the secretion of platelet granules, giving rise to compromised platelet function. Therefore, we aimed to investigate platelet degranulation in patients heterozygous for variants in UNC13D, STX11 and STXBP2. During the work-up of patients referred to the Coagulation Unit, Skåne University Hospital, Malmö, Sweden and the Department of Hematology, Rigshospitalet, Copenhagen, Denmark due to bleeding tendencies, 12 patients harboring heterozygous variants in UNC13D, STX11 or STXBP2 were identified using targeted whole exome sequencing. Transmission electron microscopy (TEM) was used to assess the secretion of platelet dense granules following thrombin stimulation. Platelet degranulation, activation and aggregation were further assessed by flow cytometry (FC) and light transmission aggregometry (LTA) with lumi-aggregometry. In total, eight out of twelve (67%) patients showed impaired degranulation by at least one of the assays (TEM, FC and LTA). In the 12 patients, eight different heterozygous variants were identified. One variant was strongly associated with impaired degranulation, while four of the variants were associated with impaired granule secretion to a slightly lesser extent. One additional variant was found in six out of the twelve patients, and was associated with varying degrees of degranulation impairment. Accordingly, six out of the eight (75%) identified variants were associated with impaired platelet degranulation. Our results suggest that heterozygous variants in UNC13D, STX11 and STXBP2 are sufficient to cause platelet secretion defects resulting in increased bleeding.
- Published
- 2018
- Full Text
- View/download PDF
9. Characterization of miRNA expression in human degenerative lumbar disks.
- Author
-
Ohrt-Nissen S, Døssing KB, Rossing M, Lajer C, Vikeså J, Nielsen FC, Friis-Hansen L, and Dahl B
- Subjects
- Humans, In Situ Hybridization, MicroRNAs metabolism, Muscles metabolism, Muscles pathology, Polymerase Chain Reaction, Principal Component Analysis, Reproducibility of Results, Signal Transduction genetics, Gene Expression Profiling, Gene Expression Regulation, Intervertebral Disc pathology, Intervertebral Disc Degeneration genetics, Lumbar Vertebrae pathology, MicroRNAs genetics
- Abstract
Background Data: microRNAs (miRNAs) are short ∼22 nucleotide RNA sequences that regulate messengerRNA translation. miRNAs have shown to play a role in synthesis of inflammatory mediators. Since inflammation play a role in intervertebral disk (IVD) degeneration, the objective was to isolate miRNA from human lumbar intervertebral disks and subsequently characterize the difference in miRNA expression between the annulus fibrosus (AF) and nucleus pulposus (NP)., Methods: Fourteen patients undergoing anterior interbody fusion for degenerative disk disease of the lumbar spine were included. During surgery biopsies from the intervertebral disks were obtained and immediately placed in RNAlater. The RNAlater was decanted and the samples frozen at -80˚C until RNA extraction. This was performed using the Trizol method. Global miRNA expression analysis was performed using the Affymetrix GeneChip® miRNA array., Results: We developed a method allowing the extraction of miRNA from human intervertebral disks usually yielding 1-4 µg of total RNA pr. 100 mg of disk. Twenty-seven miRNAs had a higher expression in the AF and 10 had the highest expression in the NP. Among the top 15 signaling pathways most likely to be controlled by these miRNAs were the transforming growth factor β (TGFβ), platelet-derived growth factor (PDGF), insulin-like growth factor (IGF) epidermal growth factor (EGF), and actin cytoskeletal pathway., Conclusion: We have demonstrated the presence of miRNA in the human IVD. The miRNA expression differs from muscle tissue and there are differences between the miRNA expressed in the NP and AF. The miRNAs identified control signaling pathways important for maintenance of the IVD. Future studies may determine the importance of miRNA in the development of IVD disease.
- Published
- 2013
- Full Text
- View/download PDF
10. A simple procedure for routine RNA extraction and miRNA array analyses from a single thyroid in vivo fine needle aspirate.
- Author
-
Rossing M, Kaczkowski B, Futoma-Kazmierczak E, Glud M, Klausen M, Faber J, Nygaard B, Kiss K, Sørensen CH, Nielsen FC, Bennedbæk FN, and Friis-Hansen L
- Subjects
- Biopsy, Fine-Needle, Gene Expression Profiling, Gene Expression Regulation, Humans, MicroRNAs metabolism, Reproducibility of Results, MicroRNAs genetics, MicroRNAs isolation & purification, Oligonucleotide Array Sequence Analysis methods, Thyroid Gland metabolism, Thyroid Gland pathology
- Abstract
Context: microRNA (miRNA) expression profiling and classification of tissue obtained from fine-needle aspirates (FNA) could be a major improvement of the preoperative diagnosis of thyroid nodules., Objective: Before this can be clinically implemented, a robust and non-toxic method for obtaining sufficient quantity and quality of RNA from single in vivo FNA has to be established. RNAlater is a non-toxic RNA-stabilizing agent. However, due to the high density of RNAlater, pelleting of the tissue samples is difficult, and results in low recovery of RNA that is insufficient for subsequent miRNA array expression analysis. We therefore developed a simple centrifugation method for capturing tissue stored in RNAlater on a 0.45-μm filter., Design: FNA from 24 patients with a solitary cold thyroid nodule was stored in Trizol, liquid nitrogen, or RNAlater. The tissue stored in RNAlater was either pelleted by centrifugation or captured on the 0.45-μm filters. RNA was extracted using the Trizol method. To validate results, FNA from additional 30 patients were analyzed based on the modified RNAlater protocol., Main Outcome: Capturing FNA tissue samples on the filters increased the RNA yield 10 fold and maintained RNA purity, permitting miRNA array expression profiling and allowing comparable levels of known miRNA-clusters regardless of preservation technique. Results were confirmed in an additional 30 patients., Conclusion: The modified RNAlater protocol is well suited for isolating RNA from single thyroid in vivo FNA in a clinical setting. Furthermore this permits shipping of FNA samples at room temperature from peripheral centers to a centralized array core facility.
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.